MedTrace Logo

Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

NCT06722664 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2025-04-29

No results posted yet for this study

Summary

Study was designed to evaluate efficacy of OsrhCT and Dimethicone emulsion before upper endoscopy on visibility of gastric mucosa.

A total of 336 subjects (both male and female) are expected to be enrolled in this trial.

Conditions

  • Gastric Mucosal Lesion

Interventions

DRUG

Recombinant Human Chymotrypsin(OsrhCT) 4000U

Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder

DRUG

Placebo for Recombinant Human Chymotrypsin(OsrhCT)

Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder

DRUG

Dimethicone emulsion 4ml

Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.

Sponsors & Collaborators

  • Beijing Friendship Hospital

    collaborator OTHER

  • Healthgen Biotechnology Corp.

    lead INDUSTRY

Principal Investigators

  • Shutian Zhang, MD · Beijing Friendship Hospital

  • Fandong Meng, MD · Beijing Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-19
Primary Completion
2025-05-15
Completion
2025-05-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06722664 on ClinicalTrials.gov